Scholarlink

Background <p>Emerging evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may help to reduce alcohol consumption in patients with alcohol use disorder (AUD). Given recent findings indicating their potential effectiveness in alcohol-related liver disease (ArLD), this study aims to systematically review the role of GLP-1RAs in patients with ArLD or AUD.</p> Methods <p>Based on the PRISMA guidelines, eligible studies included adults with AUD or ArLD treated with GLP-1RAs. The primary outcome was the development of hepatic decompensation.</p> Results <p>Six studies encompassing 1,332,698 participants were included in this study. In the three studies included in this meta-analysis, we demonstrated that GLP-1 RA therapy in patients with ArLD and T2D significantly reduced the risk of hepatic decompensation (hazard ratio (HR): 0.64; 95% CI 0.51–0.79; <i>p</i> &lt; 0.0001; I<sup>2</sup> = 0%). While individual studies showed mixed results regarding other liver-related outcomes, consistent benefits were observed in reducing mortality and liver failure in selected cohorts. In patients with AUD, GLP-1 RAs were associated with a reduced risk of developing ArLD (HR, 0.62; 95% CI 0.44–0.87) and all-cause mortality (HR, 0.53; <i>p</i> &lt; 0.001).</p> Conclusions <p>GLP-1RAs may offer favorable hepatic and survival outcomes in patients with AUD and/or ArLD, especially in those with type 2 diabetes. Despite promising observational findings, the lack of RCTs has impeded strong recommendations.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 receptor agonists in patients with alcohol use disorder and related liver disease: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月18日

查看全文
  • Pedram Pirmoradian,
  • Elahe Karimi,
  • Sara Montazeri Namin,
  • Ashkan Bahrami,
  • Bahar Darouei,
  • Reza Amani-Beni,
  • Pouya Ebrahimi,
  • Mahsa Rezasoltani,
  • Mohammad Javad Namazi,
  • Seyed MohammadReza Hashemian,
  • Seyed Masoud Moeini Taba,
  • Sajad Armanfar,
  • Salman Bashzar,
  • Reza Eshraghi

摘要

Background

Emerging evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may help to reduce alcohol consumption in patients with alcohol use disorder (AUD). Given recent findings indicating their potential effectiveness in alcohol-related liver disease (ArLD), this study aims to systematically review the role of GLP-1RAs in patients with ArLD or AUD.

Methods

Based on the PRISMA guidelines, eligible studies included adults with AUD or ArLD treated with GLP-1RAs. The primary outcome was the development of hepatic decompensation.

Results

Six studies encompassing 1,332,698 participants were included in this study. In the three studies included in this meta-analysis, we demonstrated that GLP-1 RA therapy in patients with ArLD and T2D significantly reduced the risk of hepatic decompensation (hazard ratio (HR): 0.64; 95% CI 0.51–0.79; p < 0.0001; I2 = 0%). While individual studies showed mixed results regarding other liver-related outcomes, consistent benefits were observed in reducing mortality and liver failure in selected cohorts. In patients with AUD, GLP-1 RAs were associated with a reduced risk of developing ArLD (HR, 0.62; 95% CI 0.44–0.87) and all-cause mortality (HR, 0.53; p < 0.001).

Conclusions

GLP-1RAs may offer favorable hepatic and survival outcomes in patients with AUD and/or ArLD, especially in those with type 2 diabetes. Despite promising observational findings, the lack of RCTs has impeded strong recommendations.

Graphical Abstract